MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$6,731K
Free Cash flow
-$17,251K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sale of common sto...
Change in fair value of warrant ...
Accrued expenses
Others
Negative Cash Flow Breakdown
Net income (loss)
Proceeds from issuance of common...
Lease liability
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-38,905
-8,861
-29,496
-11,269
Depreciation expense
171
149
163
195
Impairment of fixed assets
-
-
7
1
Loss on the sale and disposal of fixed assets
-
-
33
-328
Non-cash stock compensation expense
2,858
1,452
1,290
1,163
Non-cash lease expense
94
92
89
81
Non-cash interest expense
40
39
35
34
Change in fair value of warrant liabilities
12,278
-7,643
13,519
-1,146
Accretion of debt discount
316
306
263
21
Prepaid expenses and other current assets
-192
1,260
-1,202
-61
Other assets
-10
21
2
40
Accounts payable
2,384
1,698
33
-744
Accrued expenses
3,512
-3,858
2,289
1,208
Deferred income
-22
-22
178
-
Lease liability
-110
-108
-105
-129
Net cash used in operating activities
-17,182
-18,037
-10,568
-10,236
Purchase of fixed assets
69
675
409
144
Proceeds from the sale of fixed assets
-
-
0
27
Net cash used in investing activities
-69
-675
-409
-117
Proceeds from term loan, net of issuance costs
-
-
47,946
-
Proceeds from issuance of common stock in registered direct offering, net of issuance costs
-
-
0
-713
Proceeds from sale of common stock, net of issuance costs
-
-
-
0
Proceeds from option exercises
31
28
4
20
Principal payments on term loan payable to a bank
-
-
-4,233
-2,500
Proceeds from issuance of common stock in offering-Public Offering
-299
93,787
-
-
Payment of deferred debt issuance costs
-
-
-
178
Proceeds from sale of common stock through at-the-market offerings, net of issuance costs-At The Market Offering
24,250
-
5,038
-
Net cash provided by financing activities
23,982
93,815
43,895
-3,371
Net increase (decrease) in cash, cash equivalents and restricted cash
6,731
75,103
32,918
-13,724
Cash, cash equivalents and restricted cash at beginning of period
195,250
120,147
87,229
102,920
Cash, cash equivalents and restricted cash at end of period
201,981
195,250
120,147
87,229
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sale of
common stock through...
$24,250K
Proceeds from option
exercises
$31K
(-93.70%↓ Y/Y)
Net cash provided by
financing activities
$23,982K
(53.99%↑ Y/Y)
Canceled cashflow
$299K
Net increase
(decrease) in cash, cash...
$6,731K
(442.20%↑ Y/Y)
Canceled cashflow
$17,251K
Proceeds from issuance of
common stock in...
-$299K
Change in fair value of
warrant liabilities
$12,278K
(159.68%↑ Y/Y)
Accrued expenses
$3,512K
(382.54%↑ Y/Y)
Non-cash stock
compensation expense
$2,858K
(109.53%↑ Y/Y)
Accounts payable
$2,384K
(57.57%↑ Y/Y)
Accretion of debt discount
$316K
(315.79%↑ Y/Y)
Prepaid expenses and
other current assets
-$192K
(-110.84%↓ Y/Y)
Depreciation expense
$171K
(-64.89%↓ Y/Y)
Non-cash lease expense
$94K
(-37.75%↓ Y/Y)
Non-cash interest
expense
$40K
(-42.03%↓ Y/Y)
Other assets
-$10K
(44.44%↑ Y/Y)
Net cash used in
operating activities
-$17,182K
(1.86%↑ Y/Y)
Net cash used in
investing activities
-$69K
(-102.94%↓ Y/Y)
Canceled cashflow
$21,855K
Net income (loss)
-$38,905K
(-1606.19%↓ Y/Y)
Purchase of fixed assets
$69K
(102.94%↑ Y/Y)
Lease liability
-$110K
(60.00%↑ Y/Y)
Deferred income
-$22K
Buy us a coffee
Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. (CADL)